We are a pharmaceutical company dedicated to prioritizing essential medicines and aspiring to improve the health of millions of people around the world. Since our establishment in 2008, our portfolio has grown through the acquisition of 'princeps' medicines from major pharmaceutical companies. We focus on essential medicines recognized by the medical community for their therapeutic value, ensuring their production, marketing, and promotion to healthcare professionals. In doing so, we contribute each year to improving the health of over 2.5 million patients worldwide. Juvisé Pharmaceuticals is now an internationally recognized company, with medicines in neuroscience, gastroenterology, oncology (breast and prostate cancer), cardiology, and rheumatology available in nearly 80 countries worldwide. Built on a decentralized and high-performing model, our team focuses on key functions with high added value and relies on a strong network of external partners. For more information, visit: http://www.juvisepharmaceuticals.com
2008
Juvisé Pharmaceuticals raised undisclosed on March 1, 2020
Investors: Idinvest Partners